Two compounds binding the same receptor do not necessarily produce the same downstream profile the binding conformation determines which coupled signaling pathways are preferentially activated
To view or add a comment, sign in Next-Generation GLP-1Based Therapies for Obesity: Comparative Weight Loss Outcomes Mean Percentage Weight Loss in Phase 3 Trials Orforglipron (oral GLP-1 receptor agonist) 6 mg: 7.5% 36 mg: 11.0% Placebo: 2.0% n 3,100
Consult your doctor and maintain open communication with them to find the right solutions for managing these side effects and achieving your long-term health goals
Locatelli C, Pedrosa RC, De Bem AF, Creczynski-Pasa TB, Cordova CA, Wilhelm-Filho D
And let me just say, sometimes we'll try hormone replacement therapy and we're doing lifestyle and it's still not working, and that's when we'll be like, okay, maybe we should consider a GLP one